Top

Published in:

01-12-2020 | Review Article

Research progress of tumor microenvironment and tumor-associated macrophages

Authors: W. Liang, X. Huang, C. J. J. Carlos, X. Lu

Published in: Clinical and Translational Oncology | Issue 12/2020

Abstract

Cancer is a health issue causing utmost concern and continuing to be one of the leading causes of mortality worldwide. Effective tumor eradication methods that will improve the prognosis and prolong human life are an important topic in modern medicine. Increasing amounts of evidence indicate that the tumor microenvironment plays a significant role in tumor development and migration. Macrophages are important immune cells that commonly infiltrate the tumor microenvironment. Several studies found that macrophages play different roles in the process of cancer development. This article focuses on the tumor microenvironment and the generation, classification, and function of tumor-associated macrophages as well as their significance for tumor immunotherapy and other aspects, it summarizes nearly 10 years of tumor microenvironment and tumor-associated macrophage research, providing a novel insight for tumor immunotherapy.

Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003;3(6):453–8. https://doi.org/10.1038/nrc1098.CrossRefPubMed

Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–98. https://doi.org/10.1038/nrc.2016.73.CrossRefPubMed

Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009;25(1):30–8. https://doi.org/10.1016/j.tig.2008.10.012.CrossRefPubMed

Hede K. Environmental protection: studies highlight importance of tumor microenvironment. J Natl Cancer I. 2004;96(15):1120–1. https://doi.org/10.1093/jnci/96.15.1120.CrossRef

Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27(45):5904–12. https://doi.org/10.1038/onc.2008.271.CrossRefPubMedPubMedCentral

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

De Wever O, Van Bockstal M, Mareel M, Hendrix A, Bracke M. Carcinoma-associated fibroblasts provide operational flexibility in metastasis. Semin Cancer Biol. 2014;25:33–46. https://doi.org/10.1016/j.semcancer.2013.12.009.CrossRefPubMed

Bergamaschi A, Tagliabue E, Srlie T, Naume B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P, Kosma VM, Ménard S, Børresen-Dale AL. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. 2008;214(3):357–67. https://doi.org/10.1002/path.2278.CrossRefPubMed

Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009;11(1):R7. https://doi.org/10.1186/bcr2222.CrossRefPubMedPubMedCentral

10.

Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. New Engl J Med. 1986;315(26):1650–9. https://doi.org/10.1158/2326-6066.CIR-14-0209.CrossRefPubMed

11.

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. https://doi.org/10.1038/nature01322.CrossRefPubMedPubMedCentral

12.

De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol. 2003;200(4):429–47. https://doi.org/10.1002/path.1398.CrossRefPubMed

13.

Nazareth MR, Broerick L, Simpson-Abelson MR, Kelleher RJ Jr, Yokota SJ, Bankert RB. Charaterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol. 2007;178(9):5552–62. https://doi.org/10.4049/jimmunol.178.9.5552.CrossRefPubMed

14.

Gonda TA, Varro A, Wang TC, Tycko B. Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy? Semin Cell Dev Biol. 2010;21(1):2–10. https://doi.org/10.1016/j.semcdb.2009.10.001.CrossRefPubMed

15.

Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol. 2014;25(2):47–60. https://doi.org/10.1016/j.semcancer.2014.01.005.CrossRefPubMed

16.

Junttila MR, de Sauvage FJ. Influence of tumour microenvironment heterogeneity on therapeutic response. Nature. 2013;501(7467):346–54. https://doi.org/10.1038/nature12626.CrossRefPubMed

17.

Pena C, Cespedes MV, Lindh MB, Kiflemariam S, Mezheyeuski A, Edqvist PH, Hägglöf C, Birgisson H, Bojmar L, Jirström K, Sandström P, Olsson E, Veerla S, Gallardo A, Sjöblom T, Chang AC, Reddel RR, Mangues R, Augsten M, Ostman A. STC1 expression by cancer associated fibroblasts drives metastasis of colorectal cancer. Cancer Res. 2013;73(4):1287–97. https://doi.org/10.1158/0008-5472.CAN-12-1875.CrossRefPubMed

18.

Augsten M, Hagglof C, Olsson E, Stolz C, Tsagozis P, Levchenko T, Frederick M, Borg Å, Micke P, Egevad L, Östman A. CXCL14 is an autocrine growth factor for fbroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci USA. 2009;106(9):3414–9. https://doi.org/10.1073/pnas.0813144106.CrossRefPubMedPubMedCentral

19.

Augsten M, Sjoberg E, Frings O, Vorrink SU, Frijhoff J, Olsson E, Borg Å, Östman A. Cancer-associated fibroblasts expressing CXCL14 rely upon NOS1-derived nitric oxide signaling for their tumor-supporting properties. Cancer Res. 2014;74(11):2999–3010. https://doi.org/10.1158/0008-5472.CAN-13-2740.CrossRefPubMed

20.

Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A. The history of angiogenic switch concept. Leukemia. 2007;21(1):44–52. https://doi.org/10.1038/sj.leu.2404402.CrossRefPubMed

21.

St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW. Genes expressed in human tumor endothelium. Science. 2000;289(5482):1197–2002. https://doi.org/10.1126/science.289.5482.1197.CrossRefPubMed

22.

Dirat B, Bochet L, Dabek M, Daviaud D, Dauvillier S, Majed B, Wang YY, Meulle A, Salles B, Le Gonidec S, Garrido I, Escourrou G, Valet P, Muller C. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 2011;71(7):2455–65. https://doi.org/10.1158/0008-5472.CAN-10-3323.CrossRefPubMed

23.

Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat immunol. 2013;14(10):1014–22. https://doi.org/10.1038/ni.2703.CrossRefPubMedPubMedCentral

24.

Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13(10):739–52. https://doi.org/10.1038/nrc3581.CrossRefPubMedPubMedCentral

25.

Trikha P, Carson EW III. Signaling pathways involved in MDSC regulation. Biochim Biophys Acta. 2014;1846(1):55–65. https://doi.org/10.1016/j.bbcan.2014.04.003.CrossRefPubMedPubMedCentral

26.

Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity. Clin Cancer Res. 2014;20(15):4096–106. https://doi.org/10.1158/1078-0432.CCR-14-0635.CrossRefPubMed

27.

Yu F, Shi Y, Wang J, Li J, Fan DP, Ai WD. Deficiency of Kruppel-like factor KLF4 in mammary tumor cells inhibits tumor growth and pulmonary metastasis and is accompanied by compromised recruitment of myeloid-derived suppressor cells. Int J Cancer. 2013;133(12):2872–83. https://doi.org/10.1002/ijc.28302.CrossRefPubMedPubMedCentral

28.

Wang J, Yu F, Jia X, Iwanowycz S, Wang Y, Huang S, Ai W, Fan D. MicroRNA-155 deficiency enhances the recruitment and functions of myeloid-derived suppressor cells in tumor microenvironment and promotes solid tumor growth. Int J Cancer. 2015;136(6):602–13. https://doi.org/10.1002/ijc.29151.CrossRef

29.

Liu J, Zhang Y, Zhao J, Yang Z, Li D, Katirai F, Huang B. Mast cell: insight into remodeling a tumor microenvironment. Cancer Metastasis Rev. 2011;30(2):177–84. https://doi.org/10.1007/s10555-011-9276-1.CrossRefPubMed

30.

Saleem SJ, Martin RK, Morales JK, Sturgill JL, Gibb DR, Graham L, Bear HD, Manjili MH, Ryan JJ, Conrad DH. Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity. J Immunol. 2012;189(2):511–5. https://doi.org/10.4049/jimmunol.1200647.CrossRefPubMed

31.

Spano D, Zollo M. Tumor microenvironment: a main actor in the metastasis process. Clin Exp Metastasis. 2012;29(4):381–95. https://doi.org/10.1007/s10585-012-9457-5.CrossRefPubMed

32.

Gillies ER, Goodmin AP, Frechet JMJ. Acetals as pH-sensitive linkages for drug delivery. Bioconjugate chem. 2004;15(16):1254–63. https://doi.org/10.1016/S1350-4487(03)00156-2.CrossRef

33.

Felber AE, Dufresne MH, Leroux JC. pH-sensitive Vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. Adv Drug Deliver Rev. 2011;64(11):979–92. https://doi.org/10.1016/j.addr.2011.09.006.CrossRef

34.

Lisanti MP, Martinez-Outschoorn UE, Sotgia F. Oncogenes induce the cancer-associated fibroblast phenotype metabolic symbiosis and “fibroblast addiction” are new therapeutic targets for drug discovery. Cell Cycle. 2013;12(17):2723–32. https://doi.org/10.4161/cc.25695.CrossRefPubMedPubMedCentral

35.

Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32(5):593–604. https://doi.org/10.1016/j.immuni.2010.05.007.CrossRefPubMed

36.

Gordon S, Plüddemann A, Martinez EF. Macrophage heterogeneity in tissues: phenotypic diversity and functions. Immunol Rev. 2015;262(1):36–55. https://doi.org/10.1111/imr.12223.CrossRef

37.

Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med. 1992;176(1):287–92. https://doi.org/10.1084/jem.176.1.287.CrossRefPubMed

38.

Gordon S, Mantovani A. Diversity and plasticity of mononuclear phagocytes. Eur J Immunol. 2011;41(9):2470–2. https://doi.org/10.1002/eji.201141988.CrossRefPubMed

39.

Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229(2):176–85. https://doi.org/10.1002/path.4133.CrossRefPubMed

40.

Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889–96. https://doi.org/10.1038/ni.1937.CrossRefPubMed

41.

Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958–69. https://doi.org/10.1038/nri2448.CrossRefPubMedPubMedCentral

42.

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44. https://doi.org/10.1038/nature07205.CrossRefPubMed

43.

Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953–64. https://doi.org/10.1038/nri1733.CrossRefPubMed

44.

Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–55. https://doi.org/10.1016/S1471-4906(02)02302-5.CrossRefPubMed

45.

Hume DA. The many alternative faces of macrophage activation. Front Immunol. 2015;6:370. https://doi.org/10.3389/fimmu.2015.00370.CrossRefPubMedPubMedCentral

46.

Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23–35. https://doi.org/10.1038/nri978.CrossRefPubMed

47.

Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol. 2009;9(4):259–70. https://doi.org/10.1038/nri2528.CrossRefPubMedPubMedCentral

48.

Eubank TD, Roberts RD, Khan M, Curry JM, Nuovo GJ, Kuppusamy P, Marsh CB. Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res. 2009;69(5):2133–40. https://doi.org/10.1158/0008-5472.CAN-08-1405.CrossRefPubMedPubMedCentral

49.

Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010;22(2):231–7. https://doi.org/10.1016/j.coi.2010.01.009.CrossRefPubMed

50.

Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr-Relat Cancer. 2008;15(4):1069–74. https://doi.org/10.1677/ERC-08-0036.CrossRefPubMedPubMedCentral

51.

Muraille E, Leo O, Moser M. TH1/TH2 paradigm extended: macrophage polarization as an unappreciated pathogen-driven escape mechanism? Front Immunol. 2014;5:603. https://doi.org/10.3389/fimmu.2014.00603.CrossRefPubMedPubMedCentral

52.

Caronni N, Savino B, Bonecchi R. Myeloid cells in cancer-related inflammation. Immunobiology. 2015;220(2):249–53. https://doi.org/10.1016/j.imbio.2014.10.001.CrossRefPubMed

53.

Mantovani A, Locati M. Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. Arterioscl Throm Vas. 2013;33(7):1478–83. https://doi.org/10.1161/atvbaha.113.300168.CrossRef

54.

Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25(12):677–86. https://doi.org/10.1016/j.it.2004.09.015.CrossRefPubMed

55.

Chen S, Yang X, Feng W, Yang F, Wang R, Chen C, Wang L, Lin Y, Ren Q, Zheng G. Characterization of peritoneal leukemia-associated macrophages in Notch 1 induced mouse T cell acute lymphoblastic leukemia. Mol Immunol. 2017;81:35–41. https://doi.org/10.1016/j.molimm.2016.11.014.CrossRefPubMed

56.

Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012;22(1):33–40. https://doi.org/10.1016/j.semcancer.2011.12.005.CrossRefPubMed

57.

Allavena P, Sica A, Garlanda C, Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev. 2008;222(1):155–61. https://doi.org/10.1111/j.1600-065X.2008.00607.x.CrossRefPubMed

58.

Liu Y, Cao X. The origin and function of tumor-associated macrophages. Cell Mol Immunol. 2015;12(1):1–4. https://doi.org/10.1038/cmi.2014.83.CrossRefPubMed

59.

Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122(3):787–95. https://doi.org/10.1172/JCI59643.CrossRefPubMedPubMedCentral

60.

Wang B, Li Q, Qin L, Zhao S, Wang J, Chen X. Transition of tumor-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumor progression in mice. BMC Immunol. 2011;12(1):43. https://doi.org/10.1186/1471-2172-12-43.CrossRefPubMedPubMedCentral

61.

Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol. 2014;5:75. https://doi.org/10.3389/fphys.2014.00075.CrossRefPubMedPubMedCentral

62.

Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006;66(23):11238–46. https://doi.org/10.1158/0008-5472.CAN-06-1278.CrossRefPubMed

63.

Chen P, Huang Y, Bong R, Ding Y, Song N, Wang X, Song X, Luo Y. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clin Cancer Res. 2011;17(23):7230–9. https://doi.org/10.1158/1078-0432.CCR-11-1354.CrossRefPubMed

64.

Bingle L, Lewis CE, Corke KP, Reed MWR, Brown NJ. Macrophages promote angiogenesis in human breast tumour spheroids in vivo. Brit J Cancer. 2006;94(1):101–7. https://doi.org/10.1038/sj.bjc.6602901.CrossRefPubMed

65.

Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer I. 2002;94(15):1134–42. https://doi.org/10.1093/jnci/94.15.1134.CrossRef

66.

Guiet R, Van Goethem E, Gugoule C, Balor S, Valette A, Al Saati T, Lowell CA, Le Cabec V, Maridonneau-Parini I. The process of macrophage migration promotes matrix metalloproteinase-independent invasion by tumor cells. J Immunol. 2011;187(7):3806–14. https://doi.org/10.4049/jimmunol.1101245.CrossRefPubMed

67.

Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard JW, Condeelis J. Direct visualization of macrophage assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007;67(6):2649–56. https://doi.org/10.1158/0008-5472.CAN-06-1823.CrossRefPubMed

68.

Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condellis J. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004;64(19):7022–9. https://doi.org/10.1158/0008-5472.CAN-04-1449.CrossRefPubMed

69.

Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457(7225):102–6. https://doi.org/10.1038/nature07623.CrossRefPubMedPubMedCentral

70.

Gil-Bernabé AM, Ferjancic S, Tlalka M, Zhao L, Allen PD, Im JH, Watson K, Hill SA, Amirkhosravi A, Francis JL, Pollard JW, Ruf W, Muschel RJ. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood. 2012;119(13):3164–75. https://doi.org/10.1182/blood-2011-08-376426.CrossRefPubMed

71.

Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le QT, Giaccia AJ. Hypoxia-induced lysyl-oxidase is a critical mediator of bone marrow cell recruitment to form the pre-metastatic niche. Cancer Cell. 2009;15(1):35–44. https://doi.org/10.1016/j.ccr.2008.11.012.CrossRefPubMedPubMedCentral

72.

Parker KH, Sinha P, Horn LA, Clements VK, Yang H, Li J, Tracey KJ, Ostrand-Rosenberg S. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res. 2014;74(20):5723–33. https://doi.org/10.1158/0008-5472.CAN-13-2347.CrossRefPubMedPubMedCentral

73.

Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med. 2009;206(6):1327–37. https://doi.org/10.1084/jem.20082173.CrossRefPubMedPubMedCentral

74.

Van Esch EM, van Poelgeest MI, Trimbos JB, Fleuren GJ, Jordanova ES, van der Burg SH. Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPV-induced vulvar neoplasia. Int J Cancer. 2015;136(4):E85–E94. https://doi.org/10.1002/ijc.29173.CrossRefPubMed

75.

Eruslanov E, Stoffs T, Kim WJ, Daurkin I, Gilbert SM, Su LM, Vieweg J, Daaka Y, Kusmartsev S. Expansion of CCR8+ inflammatory myeloid cells in cancer patients with urothelial and renal carcinomas. Clin Cancer Res. 2013;19(7):1670–80. https://doi.org/10.1158/1078-0432.CCR-12-2091.CrossRefPubMedPubMedCentral

76.

Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5(6):471–84. https://doi.org/10.1038/nrd2059.CrossRefPubMed

77.

Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009;9(5):353–63. https://doi.org/10.1038/nri2545.CrossRefPubMedPubMedCentral

Title: Research progress of tumor microenvironment and tumor-associated macrophages
Authors: W. Liang
X. Huang
C. J. J. Carlos
X. Lu
Publication date: 01-12-2020
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 12/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-020-02367-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2020

The free amino acid profiles and metabolic biomarkers of predicting the chemotherapeutic response in advanced sarcoma patients

A population perspective on the use of external beam radiotherapy in Catalonia, Spain

Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma

LncRNA DCST1-AS1 downregulates miR-29b through methylation in glioblastoma (GBM) to promote cancer cell proliferation

Indicators of a pro-tumor immune response are evident at early stages of breast cancer

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer